3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
5
Carcinoid Tumor
3
Serotonin Syndrome
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors in Lung
1
Neoplasm Metastasis
1
Gigantism
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Flushing
1
Endocrine Tumors
1
Diarrhea
1
Acromegaly
1
Interventions
lutetium Lu 177 dotatate
2
pembrolizumab
1
pasireotide
1
lanreotide
1
folfirinox
1
copper dotatate CU-64
1
arginyllysine
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Octreotide
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Cytokines
1
Cryotherapy
1
Carboplatin
1
Acupuncture Therapy
1
Acupressure
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Gastro-enteropancreatic neuroendocrine tumor
×
lanreotide
×
Clear all
NCT03043664
2023-06-29
PLANET
Duke University
Phase 1/2
Completed
22 enrolled
12 charts